What is the next best investigation for a child with Henoch-Schönlein Purpura (HSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Next Best Investigation for a Child with Henoch-Schönlein Purpura (HSP)

Urinalysis with microscopic examination is the most important initial investigation for a child with HSP to assess for renal involvement, which is the primary determinant of long-term prognosis.

Initial Evaluation for Renal Involvement

Urinalysis Assessment

  • Urinalysis with microscopy should be performed immediately to detect:
    • Hematuria (microscopic or macroscopic)
    • Proteinuria (quantitative measurement)
    • Red blood cell casts
    • Deformed red blood cells (using phase contrast microscopy) 1

Additional Basic Laboratory Tests

  • Complete blood count with platelets
  • Blood urea nitrogen (BUN)
  • Serum creatinine
  • Spot urine protein-to-creatinine ratio (for quantification of proteinuria)

Monitoring Protocol

  • Urinalysis should be performed:
    • Weekly for the first month after diagnosis
    • Every 2 weeks for the second month
    • Monthly for the next 4-6 months
    • Then every 3 months until 1 year after diagnosis 1, 2

Indications for Renal Biopsy

Renal biopsy should be performed in children with HSP who present with:

  • Decreased renal function at presentation
  • Severe nephrotic syndrome or nephritic syndrome
  • Persistent heavy proteinuria (>1 g/day/1.73 m²) despite optimal therapy with ACE inhibitors/ARBs for 3-6 months 1, 2

Risk Stratification Based on Initial Findings

Low Risk

  • Normal urinalysis or minimal abnormalities
  • Continue monitoring with serial urinalysis

Moderate Risk

  • Persistent proteinuria (0.5-1 g/day/1.73 m²)
  • Consider ACE inhibitor or ARB therapy 1, 2

High Risk

  • Nephrotic-range proteinuria
  • Elevated creatinine
  • Hypertension
  • Consider renal biopsy and more aggressive therapy 1

Important Clinical Considerations

  • Renal involvement occurs in approximately 20-60% of children with HSP 3, 4
  • Most children develop renal manifestations within 2 weeks of disease onset, while adults may develop hematuria up to 5 weeks after onset 5
  • Factors associated with higher risk of nephritis include:
    • Older age at onset
    • GI bleeding
    • Central nervous system involvement 6
    • Persistent purpura for >1 month 5

Common Pitfalls to Avoid

  1. Inadequate follow-up duration: Renal manifestations may appear weeks after the initial presentation of HSP, so monitoring should continue for at least 6 months
  2. Missing nephrotic syndrome: Patients with abdominal pain at disease onset have a significantly higher probability of developing nephrotic syndrome 5
  3. Premature discontinuation of monitoring: Even children with initially normal urinalysis should have continued monitoring as late-onset nephritis can occur
  4. Failure to recognize crescentic nephritis: This severe form requires aggressive immunosuppressive therapy and has poorer outcomes 1

Remember that renal involvement is the most important prognostic factor in determining morbidity and mortality in HSP. Early detection through appropriate urinalysis monitoring is essential for timely intervention and improved outcomes.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Henoch-Schönlein Purpura Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Henoch-Schönlein Purpura in Children: An Updated Review.

Current pediatric reviews, 2020

Research

Henoch-Schönlein nephritis: a nationwide study.

Nephron. Clinical practice, 2009

Research

Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study.

Pediatric nephrology (Berlin, Germany), 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.